Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes
试验速览
- 阶段
- 4 期
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- optimal glycemic control in inpatient cirrhotics
研究概览
简要总结
Liver disease is an important cause of death in type 2 diabetes. In the population-based Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths. In another prospective cohort study , cirrhosis accounted for 12.5% of deaths in patients with diabetes. In Egypt hepatitis C virus the commonest of cirrhosis here has a prevalence of 9.8% in the population with the greatest burden over national health care bills. Patients with cirrhosis & type 2 diabetes mellitus are always showing up in all hospital wards without a clear consensus of best management of their hyperglycemia.
详细描述
Best management of hyperglycemia in non-intensive care unit Cirrhotic patients with type 2 diabetes by different insulin regimens either sliding scale regular insulin or basal bolus insulin using NPH & regular insulin or Glargine & Glulisine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized type 2 Diabetes Mellitus with liver cirrhosis
- •Entry blood glucose (fasting or random) greater than 180 mg%
排除标准
- •Type 1 Diabetes Mellitus
- •Pregnancy
- •Steroids: prednisone greater than 7.5mg/day or equivalent
- •Serum Creatinine > 3 mg/dl
- •Patients in intensive care units.
研究组 & 干预措施
15 patient sliding scale regular insulin
干预措施: Regular insulin (Drug)
15 patient BBI NPH plus regular insulin
干预措施: NPH & regular insulin (Drug)
15 patients BBI Glargine plus Glulisine
干预措施: Glargine & Glulisine (Drug)
结局指标
主要结局
optimal glycemic control in inpatient cirrhotics
时间窗: 3-7 days
次要结局
- Incidence of hypoglycemic episodes(3-7 days)